Literature DB >> 15807874

Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.

Marianne E Pavel1, Gerda Hassler, Ulrich Baum, Eckhart G Hahn, Tobias Lohmann, Detlef Schuppan.   

Abstract

OBJECTIVE: The growth behaviour of well-differentiated neuroendocrine carcinomas of the gastro-entero-pancreatic system varies greatly and parameters predicting their prognosis are lacking. The aim of our study was to investigate whether tumour growth could be correlated with the release of proangiogenic factors into the circulation. PATIENTS AND METHODS: Circulating vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), basic fibroblast growth factor (bFGF) and angiogenin were measured in 38 patients with advanced neuroendocrine carcinomas and compared to healthy age-matched controls. In 20 patients, angiogenic cytokine levels were measured at consecutive time points and correlated to tumour progression as assessed by abdominal CT scan, MRI and chromogranin A levels.
RESULTS: VEGF levels were elevated in patients compared to controls (P < 0.002) and clearly associated with tumour progression (P < 0.005). Angiogenin levels were significantly higher in patients than in controls (P < 0.003), while high IL-8 levels were predictive of shorter survival. Angiogenin and bFGF levels were correlated neither with tumour growth nor with patient survival.
CONCLUSIONS: VEGF and IL-8 are associated with tumour progression and might qualify as markers of prognosis and therapy control in patients with neuroendocrine carcinomas. Our results support the notion that specific anti-angiogenic therapies should be evaluated in neuroendocrine carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15807874     DOI: 10.1111/j.1365-2265.2005.02238.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  22 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 2.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 3.  Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.

Authors:  P Gajate; T Alonso-Gordoa; O Martínez-Sáez; J Molina-Cerrillo; E Grande
Journal:  Clin Transl Oncol       Date:  2017-11-09       Impact factor: 3.405

4.  Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect.

Authors:  Kazuhiko Kasuya; Yuichi Nagakawa; Minako Suzuki; Hiroaki Tanaka; Hiroshi Ohta; Takao Itoi; Akihiko Tsuchida
Journal:  Exp Ther Med       Date:  2011-09-05       Impact factor: 2.447

Review 5.  Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.

Authors:  Omar Abdel-Rahman
Journal:  Tumour Biol       Date:  2014-09-18

Review 6.  The RNase a superfamily: generation of diversity and innate host defense.

Authors:  Kimberly D Dyer; Helene F Rosenberg
Journal:  Mol Divers       Date:  2006-11       Impact factor: 2.943

Review 7.  Medical treatment of gastrinomas.

Authors:  Christoph J Auernhammer; Burkhard Göke
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

8.  Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

Authors:  James C Yao; Marianne Pavel; Catherine Lombard-Bohas; Eric Van Cutsem; Maurizio Voi; Ulrike Brandt; Wei He; David Chen; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Timothy Hobday; Rodney Pommier; Kjell Öberg
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

Review 9.  Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-03       Impact factor: 4.553

10.  Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymph Nodes of NOD mice is associated with Islet Autoimmunity.

Authors:  Béatrice Regnault; José Osorio Y Fortea; Dongmei Miao; George Eisenbarth; Evie Melanitou
Journal:  BMC Med Genomics       Date:  2009-10-02       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.